Skip to main content
. 2023 Aug 21;13(14):4711–4729. doi: 10.7150/thno.85663

Figure 5.

Figure 5

A) In vivo therapeutic efficacy of AGuIX® or AGuIX-Bi (30Gd/70Bi) with or without radiation (10 Gy) in a NSCLC A549 murine model. Tumor growth relative to the tumor size on the day of irradiation is shown (n = 6 - 9 mice). Nanoparticles were given at a massic concentration of 300 mg kg-1 followed by radiation 30 mins post-AGuIX® or 24 h post-AGuIX-Bi (30Gd/70Bi) injection. Relative tumor growth for each group is presented until the day the first animal within that group dropped out. B) Time-to-tumor-doubling is indicated with endpoint failure defined as tumor volume doubling relative to Day 0. Complete tumor regression was observed in 33% of mice treated with AGuIX-Bi (30Gd/70Bi) plus radiation. C) Mean time-to-tumor doubling shows that mice treated with AGuIX-Bi (30Gd/70Bi) plus radiation had significantly longer tumor delay compared to control groups. D) No change in mouse body weight was observed following any treatment indicating no systemic toxicity (* p < 0.05, ** p < 0.01, and *** p < 0.001).